Is it time to retire efavirenz as a first-line option worldwide?

AIDS. 2022 Feb 1;36(2):317-318. doi: 10.1097/QAD.0000000000003101.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Alkynes
  • Benzoxazines / therapeutic use
  • Cyclopropanes
  • HIV Infections* / drug therapy
  • Humans

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • efavirenz